{"id":"https://openalex.org/W2005176759","doi":"https://doi.org/10.1111/j.1346-8138.2009.00748.x","title":"Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study","display_name":"Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study","publication_year":2010,"publication_date":"2010-02-26","ids":{"openalex":"https://openalex.org/W2005176759","doi":"https://doi.org/10.1111/j.1346-8138.2009.00748.x","mag":"2005176759","pmid":"https://pubmed.ncbi.nlm.nih.gov/20507398"},"language":"en","primary_location":{"id":"doi:10.1111/j.1346-8138.2009.00748.x","doi":"https://doi.org/10.1111/j.1346-8138.2009.00748.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1346-8138.2009.00748.x","pdf_url":null,"source":{"id":"https://openalex.org/S143887118","display_name":"The Journal of Dermatology","issn_l":"0385-2407","issn":["0385-2407","1346-8138"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015950702","display_name":"Akihiko Asahina","orcid":"https://orcid.org/0000-0001-6127-3182","observed_orcids":["https://orcid.org/0000-0001-6127-3182"]},"institutions":[{"id":"https://openalex.org/I4210115833","display_name":"National Sagamihara Hospital","ror":"https://ror.org/01gvfxs59","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210115833","https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Akihiko ASAHINA","raw_affiliation_strings":["National Hospital Organization Sagamihara National Hospital, Sagamihara City, Kanagawa, Japan. asahina-tky@umin.ac.jp","National Hospital Organization Sagamihara National Hospital, Sagamihara City, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Hospital Organization Sagamihara National Hospital, Sagamihara City, Kanagawa, Japan. asahina-tky@umin.ac.jp","institution_ids":["https://openalex.org/I4210115833"]},{"raw_affiliation_string":"National Hospital Organization Sagamihara National Hospital, Sagamihara City, Kanagawa, Japan","institution_ids":["https://openalex.org/I4210115833"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068242406","display_name":"Hidemi Nakagawa","orcid":"https://orcid.org/0000-0002-8272-4488","observed_orcids":["https://orcid.org/0000-0002-8272-4488"]},"institutions":[{"id":"https://openalex.org/I115498069","display_name":"Jikei University School of Medicine","ror":"https://ror.org/039ygjf22","country_code":"JP","type":"education","lineage":["https://openalex.org/I115498069"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hidemi NAKAGAWA","raw_affiliation_strings":["The Jikei University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Jikei University School of Medicine","institution_ids":["https://openalex.org/I115498069"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046156143","display_name":"Takafumi Etoh","orcid":"https://orcid.org/0009-0004-0495-9064","observed_orcids":["https://orcid.org/0009-0004-0495-9064"]},"institutions":[{"id":"https://openalex.org/I4210141191","display_name":"Tokyo Teishin Hospital","ror":"https://ror.org/04j339g17","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210141191"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takafumi ETOH","raw_affiliation_strings":["Tokyo Teishin Hospital, Tokyo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tokyo Teishin Hospital, Tokyo","institution_ids":["https://openalex.org/I4210141191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067909005","display_name":"Mamitaro Ohtsuki","orcid":"https://orcid.org/0000-0001-7845-6698","observed_orcids":["https://orcid.org/0000-0001-7845-6698"]},"institutions":[{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mamitaro OHTSUKI","raw_affiliation_strings":["Jichi Medical University School of Medicine, Tochigi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jichi Medical University School of Medicine, Tochigi, Japan","institution_ids":["https://openalex.org/I146500386"]}]},{"author_position":"last","author":{"id":null,"display_name":"THE ADALIMUMAB M04\u2010688 STUDY GROUP","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"THE ADALIMUMAB M04\u2010688 STUDY GROUP","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5015950702"],"corresponding_institution_ids":["https://openalex.org/I4210115833"],"apc_list":{"value":3630,"currency":"USD","value_usd":3630},"apc_paid":null,"fwci":5.3977,"has_fulltext":false,"cited_by_count":185,"citation_normalized_percentile":{"value":0.96482514,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"37","issue":"4","first_page":"299","last_page":"310"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":1.0},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.9509999752044678},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.843999981880188},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.8299999833106995},{"id":"https://openalex.org/keywords/loading-dose","display_name":"loading dose","score":0.9829999804496765},{"id":"https://openalex.org/keywords/pasi-75","display_name":"PASI 75","score":0.8330000042915344},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.7369999885559082},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.7329999804496765},{"id":"https://openalex.org/keywords/hepatic-adverse-events","display_name":"hepatic adverse events","score":0.8040000200271606},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.6050000190734863}],"concepts":[{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.9311694502830505},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8292757272720337},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7397482395172119},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.7190372943878174},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6271275281906128},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.5834420919418335},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5538045763969421},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5353816747665405},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3971972167491913},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.36610400676727295},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1808791160583496},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.052121251821517944},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.03904065489768982},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002908","descriptor_name":"Chronic Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044466","descriptor_name":"Asian People","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1346-8138.2009.00748.x","doi":"https://doi.org/10.1111/j.1346-8138.2009.00748.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1346-8138.2009.00748.x","pdf_url":null,"source":{"id":"https://openalex.org/S143887118","display_name":"The Journal of Dermatology","issn_l":"0385-2407","issn":["0385-2407","1346-8138"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Dermatology","raw_type":"journal-article"},{"id":"pmid:20507398","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20507398","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of dermatology","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320310945","display_name":"Abbott Japan","ror":"https://ror.org/04v748538"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W67314253","https://openalex.org/W1556049736","https://openalex.org/W1986455689","https://openalex.org/W2000735993","https://openalex.org/W2003567650","https://openalex.org/W2008716526","https://openalex.org/W2027458747","https://openalex.org/W2032110831","https://openalex.org/W2045940178","https://openalex.org/W2046628605","https://openalex.org/W2063627867","https://openalex.org/W2158090558","https://openalex.org/W2163232748","https://openalex.org/W2168841149","https://openalex.org/W2742484040","https://openalex.org/W3189725203"],"related_works":["https://openalex.org/W1524130381","https://openalex.org/W2342884636","https://openalex.org/W2063627867","https://openalex.org/W2145093133","https://openalex.org/W2295780312","https://openalex.org/W2361144571","https://openalex.org/W1608594180","https://openalex.org/W2896563744","https://openalex.org/W3214104920","https://openalex.org/W2512942811"],"abstract_inverted_index":{"Incidence":[0],"of":[1,46,51,113,209,247],"psoriasis":[2,62],"vulgaris":[3],"in":[4,11,31,53,121,206,229,244],"Asians":[5],"is":[6],"estimated":[7],"at":[8,82,92,130,221],"0.05-0.3%.":[9],"Studies":[10],"North":[12],"America":[13],"and":[14,29,44,124,186,202,219],"Europe":[15],"demonstrated":[16,217],"that":[17],"adalimumab,":[18],"a":[19,116],"fully":[20],"human,":[21],"recombinant,":[22],"immunoglobulin":[23],"G(1)":[24],"monoclonal":[25],"antibody,":[26],"was":[27,110],"efficacious":[28],"well-tolerated":[30],"patients":[32,55,114,211,230],"with":[33,56,198,213],"chronic":[34,60],"plaque":[35,61],"psoriasis.":[36,248],"This":[37],"24-week,":[38],"placebo-controlled":[39],"study":[40],"evaluated":[41],"the":[42,111,180,245],"efficacy":[43,108,218],"safety":[45,220],"three":[47,145,223],"different":[48],"dosing":[49],"regimens":[50],"adalimumab":[52,71,78,87,95,146],"Japanese":[54],"moderate":[57],"to":[58,69],"severe":[59],"(n":[63],"=":[64],"169).":[65],"Patients":[66],"were":[67,140],"randomized":[68],"receive":[70],"40":[72,88,155,232],"mg":[73,89,97,149,156,166,233],"every":[74],"other":[75],"week":[76,83,93,131,134,178],"(eow),":[77],"80-mg":[79,187,241],"loading":[80,159,184,236,242],"dose":[81,185,237,243],"0":[84],"followed":[85],"by":[86],"eow":[90,101,157,182,188,234],"starting":[91],"2,":[94],"80":[96,165],"eow,":[98],"or":[99,118],"placebo":[100,173],"given":[102],"as":[103,177],"s.c.":[104],"injections.":[105],"The":[106],"primary":[107],"endpoint":[109],"percentage":[112],"achieving":[115],"75%":[117],"greater":[119,142,192,207],"improvement":[120],"Psoriasis":[122],"Area":[123],"Severity":[125],"Index":[126],"(PASI":[127],"75)":[128],"score":[129],"16.":[132],"At":[133],"16,":[135],"PASI":[136,193],"75":[137,194],"response":[138,195,227],"rates":[139,196],"significantly":[141,191],"for":[143],"all":[144,222],"groups":[147,189],"(40":[148],"eow:":[150,167],"57.9%,":[151],"P":[152,162,169],"<":[153,163,170],"0.001;":[154,164],"plus":[158,183,235],"dose:":[160],"62.8%,":[161],"81.0%,":[168],"0.001)":[171],"versus":[172],"(4.3%).":[174],"As":[175],"early":[176],"4,":[179],"40-mg":[181],"achieved":[190],"compared":[197,212],"placebo.":[199,214],"Injection-site":[200],"reactions":[201],"hepatic":[203],"events":[204],"occurred":[205],"percentages":[208],"adalimumab-treated":[210],"Adalimumab":[215],"therapy":[216],"dosage":[224],"regimens.":[225],"Rapid":[226],"rate":[228],"receiving":[231],"supports":[238],"using":[239],"an":[240],"treatment":[246]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":12},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":12},{"year":2019,"cited_by_count":21},{"year":2018,"cited_by_count":15},{"year":2017,"cited_by_count":20},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":11},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":16},{"year":2012,"cited_by_count":13}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}